Wall Street pulls back after recent rally
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/5/2026
- Dow closes at record on Mideast optimism; SpaceX, AMD drag Nasdaq
- SpaceX tumbles amid AI spending concerns; Musk outlines $1 trillion revenue target
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
- New report warns China transceiver ban would hurt U.S. AI giants
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Opendoor posts Q2 revenue rise as net loss widens year over year
- Salesforce president Srini Tallapragada steps down, becomes advisor
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- Dave & Buster's names CFO Darin Harper as new CEO
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
BMO Capital Reiterates Outperform on Pfizer (PFE) Following Allergan Merger Termination
April 6, 2016 10:42 AM EDTBMO Capital reiterated an Outperform rating and $39.00 price target on Pfizer (NYSE: PFE) following the company's announcement the merger agreement with Allergan plc was terminated. BMO believes that Pfizer will likely look for more deals to strengthen its innovative business, and the recent weakness... More
Leerink Partners Cuts Price Target on Allergan (AGN) Following New U.S. Treasury Regulations
April 6, 2016 7:13 AM EDTLeerink Partners maintained an Outperform rating on Allergen (NYSE: AGN), and cut the price target to $272.00 (from $340.00), following new U.S. Treasury regulations. The Treasury's temporary regulation regarding new tax inversion rules creates a risk to PFE (MP) - AGN closing.
Analyst Jason Gerberry... More
Northland Capital Markets Downgrades Edwards Lifesciences (EW) to Market Perform (Earlier)
April 5, 2016 10:27 AM EDTNorthland Capital Markets downgraded Edwards Lifesciences (NYSE: EW) from Outperform to Market Perform with a price target of $105.00.
Aanalyst Suraj Kalia commented, "PARTNER-2 intermediate-risk cohort showed that SAPIEN-3 was superior to surgery @ 1-yr in the composite endpoint of all-cause death, stroke and moderate... More
Allergan (AGN), Pfizer (PFE) Comment on U.S. Treasury Action; Won't Comment on Potential Impact
April 5, 2016 6:37 AM EDTPfizer Inc. (NYSE: PFE) and Allergan plc (NYSE: AGN) issued the following statement regarding the recently issued Department of Treasury Notice:
We are conducting a review of the U.S. Department of Treasurys actions announced today. Prior to completing the review, we wont speculate on any potential impact.
... MoreStifel Raises Price Target on Edwards Lifesciences (EW) to $117; Reiterates Buy
April 4, 2016 10:33 AM EDTStifel reiterated a Buy rating on Edwards Lifesciences (NYSE: EW), and raised the price target to $117.00 (from $98.00), following data presentations at American College of Cardiology. Given the outstanding data, Stifel is increasing its 2016-2020 revenue and EPS projections. On EPS, they now project 2016 at $2.67, up $0.06 from prior estimates and 2017 moves to $3.36, up $0.36 or 12% vs prior projection.
Analyst Rick Wise... More
Tesla (TSLA) CEO Musk Says Over 276K Model 3 Pre-Orders Placed
April 4, 2016 7:54 AM EDTTesla (Nasdaq: TSLA) CEO Elon Musk offered additional updates on Model 3 pre-orders and features over the weekend.
In part, Musk said over 276,000 Model 3 pre-orders have been placed.
Musk also noted that the Model 3 will be rear-wheel drive with an option for... More
BTIG Upgrades Edwards Lifesciences (EW) to Buy
April 4, 2016 7:35 AM EDTBTIG upgraded Edwards Lifesciences (NYSE: EW) from Neutral to Buy with a price target of $115. The upgrade follows strong SAPIEN 3... More
